Cellectis SA ZVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZVA is a good fit for your portfolio.
News
-
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move
-
Cellectis Shares Soar Premarket on AstraZeneca Deal
-
Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca
-
AstraZeneca to Invest $245 Million in Deal With Cellectis
Trading Information
- Previous Close Price
- €2.19
- Day Range
- €2.07–2.07
- 52-Week Range
- €0.88–—
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €206.69 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 216
- Website
- https://www.cellectis.com
Comparables
Valuation
|
Metric
|
ZVA
|
IPH
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.77 | 3.31 | 7.56 |
Price/Sales | 30.46 | 3.29 | 772.35 |
Price/Cash Flow | — | — | — |
Price/Earnings
ZVA
IPH
FUSN
Financial Strength
|
Metric
|
ZVA
|
IPH
|
FUSN
|
|---|---|---|---|
Quick Ratio | 1.20 | 3.51 | 10.37 |
Current Ratio | 1.63 | 3.73 | 10.64 |
Interest Coverage | −13.23 | −15.79 | −18.82 |
Quick Ratio
ZVA
IPH
FUSN
Profitability
|
Metric
|
ZVA
|
IPH
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −21.54% | −2.51% | −34.33% |
Return on Equity (Normalized) | −64.28% | −9.04% | −45.42% |
Return on Invested Capital (Normalized) | −32.65% | −7.88% | −37.43% |
Return on Assets
ZVA
IPH
FUSN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Tmcdtgss | Jkzrcxs | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rzmlnmyjp | Bswcch | $114.2 Bil | |||
| Moderna Inc
MRNA
| Xlfbvnrc | Dpky | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Wpcfyxn | Pzpn | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Klnnvspg | Sfns | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ysyxwlgr | Dwrpxy | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Clhqhxp | Dzwxtc | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bqgdqcyv | Lfww | $12.8 Bil | |||
| Incyte Corp
INCY
| Lnkkxld | Ngxlw | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mknszfpdrr | Jcmrd | $12.2 Bil |